NeoImmuneTech
William Choi is an experienced professional in the biotechnology sector, currently serving as Assistant Manager at NeoImmuneTech, Inc. since November 2021. Prior to this role, William worked at ATEMs from April 2020 to November 2021, where responsibilities included developing business strategies, managing intellectual properties, and analyzing market dynamics and competitors. William also contributed to materials for Investor Relations during Series A bridge fundraising and was involved in the IPO preparation process. William holds a Master of Engineering in Bio-Engineering (2020) and a Bachelor of Engineering in Bio-Engineering (2018) from Inha University.
This person is not in any teams
This person is not in any offices
NeoImmuneTech
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech